- 21 ago.- 23:01

Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency

Business Wire.
  • The licence extension submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to treat type 2 diabetes mellitus (T2DM) patients with chronic kidney disease (CKD) will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP)
  • The CREDENCE renal outcomes study, which was stopped early due to positive efficacy findings, served as the basis for the licence extension submission
  • If approved, Invokana will be the first therapy in nearly 20 years indicated to reduce the risk of end-stage renal disease when added to current standard of care for this group of T2DM patients
  • Mundipharma has a partnership with Janssen to be the exclusive distributor for Invokana across 18 countries in the European Economic Area (EEA) and Switzerland where the products currently have Pricing and Reimbursement status. This is with the exception of Spain, where the products are co-promoted by both Janssen and Mundipharma
- 21 ago.- 21:01

Topcon parteciperà al meeting EURETINA 2019

Business Wire.

Tra gli appuntamenti più importanti del meeting spiccano un simposio e workshop sulla tomografia a coerenza ottica Swept Source e il debutto in Europa del sistema di gestione dati per cure oculistiche Topcon Harmony

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni

Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Pianeta Camere

Piani Individuali di Risparmio

Frenata lancio prodotti. Da nuove norme possibili perdite